ECTRIMS 2023 | Targeting progressive MS: the potential of the complement system

Francesca Gilli, PhD, Dartmouth College, Hanover, NH, discusses the need to target progressive multiple sclerosis (MS) and highlights the current lack of effective therapies for this stage of the disease. The focus of MS research is now on identifying new therapies specifically for progressive MS. Dr Gilli explains that the complement system, which plays a role in both the inflammatory and neurodegenerative processes, could be a promising target for these patients. By directly targeting the complement system in the central nervous system, researchers aim to reduce both inflammation and neurodegeneration in progressive MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.